SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target

Bone metastasis occurs in ~40% patients with non-small cell lung cancer (NSCLC), resulting in serious morbidity and mortality. Sclerostin domain-containing protein 1 (SOSTDC1) has been demonstrated to be associated with the development and progression of multiple types of cancer. However, the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guanghui, Gong, Haiyi, Wang, Ting, Wang, Jian, Han, Zhitao, Bai, Guangjian, Han, Shuai, Yang, Xinghai, Zhou, Wang, Liu, Tielong, Xiao, Jianru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202094/
https://www.ncbi.nlm.nih.gov/pubmed/30320379
http://dx.doi.org/10.3892/ijmm.2018.3926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202094/
https://www.ncbi.nlm.nih.gov/pubmed/30320379
http://dx.doi.org/10.3892/ijmm.2018.3926

Ejemplares similares